Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{183659,
        author = {Mrs Roshini K V and Neha Robinson and Nidha Afsal and Tania Maria Subi},
        title = {MRNA VACCINES: THE NEXT FRONTIER IN THE FIGHT AGAINST PANCREATIC CANCER- A REVIEW ARTICLE},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {12},
        number = {3},
        pages = {2454-2458},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=183659},
        abstract = {Pancreatic cancer is one of the deadliest malignancies in human beings across the globe, with its treatment accompanied by poor prognosis due to its diagnosis at late stages and resistance to the common cancer treatments, i.e. chemo and radiation.[1] The existing regimens have relatively low effectiveness and are burdened by a great deal of systemic toxicity, which further reinforces the need to develop individually crafted treatment strategies. These gaps will be occupied by new strategies like the mRNA-based cancer vaccines that are anticipated to cause minimal to no side effects and induce tumor-restricted immune responses. Very early Phase-I trials have shown that about half of the pancreatic cancer patients who are given personalized mRNA vaccines develop strong anti-tumor immune responses, pointing to the potential of this new intervention as a potentially effective, personalized therapy for pancreatic cancer that is much more aggressive and has a poor prognosis.[2]},
        keywords = {},
        month = {August},
        }